This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignees: Institut Pasteur, Assistance Publique-Hopitaux De Paris, National Institute of Health and Medical Research. Active years: 2009-2012.
Company Filing History:
2 out of 897 
1 out of 331 
1 out of 1,853 
Years Active: 2009-2012
Title: Pierre Rohrlich: Innovator in Immunogenic Peptides
Introduction
Pierre Rohrlich is a notable inventor based in Saint-Mandé, France. He has made significant contributions to the field of immunology, particularly in the development of therapeutic vaccines. With a total of 2 patents, his work focuses on optimizing immunogenic peptides for the treatment of leukemia in humans.
Latest Patents
One of Rohrlich's latest patents is titled "Mutated immunogenic peptides derived from R9M, polynucleotides coding for same and therapeutic uses thereof." This invention involves the optimization of the wild R9M peptide, which is derived from the human TEL/AML1 fusion protein. The patent details the use of these mutated immunogenic peptides for therapeutic and preventive vaccination against leukemia. It also encompasses polynucleotides coding for these peptides, cellular expression vectors, and antibodies that can bind to the peptides or polynucleotides. The ultimate goal of this invention is to prepare vaccines and anti-tumoral medicines that can stimulate the immune response in humans.
Career Highlights
Throughout his career, Pierre Rohrlich has worked with prestigious institutions such as the Institut Pasteur and the National Institute of Health and Medical Research. His experience in these organizations has allowed him to contribute to groundbreaking research in immunology and vaccine development.
Collaborations
Rohrlich has collaborated with notable colleagues, including Pierre Langlade-Demoyan and Hüseyin Firat. These partnerships have further enriched his research and innovation in the field.
Conclusion
Pierre Rohrlich's work in the optimization of immunogenic peptides represents a significant advancement in therapeutic vaccination against leukemia. His contributions continue to impact the field of immunology and hold promise for future medical applications.